Ipsen — Board/Management Information 2020

Sep 25, 2020

Ipsen appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer

PARIS, France, 25 September 2020 -- Ipsen (Euronext: IPN; ADR: IPSEY) today announced the appointment of Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer, effective 1 October 2020. Based in Cambridge, Massachusetts, USA, he will be responsible for business development and alliance management, reporting directly to David Loew, CEO, Ipsen. Philippe will serve on the Executive Leadership Team.

"As Chief Business Officer, Philippe will play a crucial role in our external innovation strategy. The ELT and I are delighted to welcome Philippe to lpsen and look forward to working closely with him. His extensive and impressive track record in international business development, his outstanding reputation and his ability to work closely with the scientific community around the world will be a tremendous asset as we continue to develop our position as a global biopharmaceutical leader via external innovation. I know Philippe will make significant contributions to our existing network of robust partnerships and will help us further strengthen our pipeline," said David Loew, CEO, Ipsen.

"I'm excited to be joining losen at this pivotal moment," said Philippe Lopes-Fernandes. "Working closely with David, the ELT and the Business Development team, I look forward to further strengthening Ipsen's alliances across its therapeutic areas to help achieve our vision of serving patients with high unmet medical needs."

Prior to joining Ipsen, Philippe worked at Merck KGaA where he was the Senior Vice President, Global Head of Business Development and Alliance Management, based in Cambridge (US). Before that, he held a variety of roles at Merck KGaA in Business Development, Mergers & Acquisitions, Finance and Marketing in France, Portugal, Germany, the United States and Switzerland.

Philippe received his degree from the Institut Supérieur de Gestion (ISG) in Paris in 1994. He is a French External Trade advisor (Conseiller du Commerce Extérieur) and board member of several companies.

He will continue to be based in Cambridge (USA).

About Ipsen

Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience, and Rare Diseases. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.5 billion in 2019, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,800 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com

Ipsen's Forward Looking Statement

The forward-looking statements, objectives and targets contained herein are based on the Group's management strategy, current views and assumptions. Such statements involve known risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group's future its financial targes. which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes", "anticipates" and "expects" and similar expressions are intentify forward-looking statements, including the Group's expectations regarding future events, including regulatory filings and the outcome of this study or other study or other studies. Moreover, the targets described in this document were prepared without takernal growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targes depend on conditions or facts likely to hapen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launchet or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that micht translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which inst that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. The Group cannot be certain that favorable results obtaincal trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the roduct concerned. There can be no quarantees a roduct will receive the necessary regulator that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertaintes materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not lindustry conditions and competition; general economic factors, including interest rate and currency exchange the impact of 6 pharmaceuical industry requlation and health care legistation; global trends toward health care cost containment; technological advances, new products and patents attained by competitions inherent in new product development, including regulatory approval; the Group's ability to acurately predict future market conditions; manufacturing difficulties or delays: financial instability of international economies and sovereign risk: dependence of the Group's patents and other prolections for ine exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potential royalties; these partners could behave in such ways which could cause damage to the Group's activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those ageements. A default by any of the Group's partners could generate lower revenues than expected. Such situations could have a negative impact on the Group's business, financial position or performance. The Group expressly disclaims any obligation to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions or circumstances on which any such statements are based, unless or equired by applicable law. The risk factors outlined in its registration documents filed with the Financies. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group's 2019 Universal Registration Document available on its website (www.ipsen.om).

For further information:

Media

Fanny Allaire Global Communications Director +33(0)1 58 33 58 96 fanny.allaire@ipsen.com

Financial Community

Eugenia Litz Vice President, Investor Relations +44 (0) 1753 627721 eugenia.litz@ipsen.com

Myriam Koutchinsky Investor Relations Manager +33 (0)1 58 33 51 04 myriam.koutchinsky@ipsen.com